Clinical Trial Detail

NCT ID NCT01376310
Title GSK1120212 Rollover Study
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements no
Sponsors GlaxoSmithKline
Indications

hematologic cancer

Advanced Solid Tumor

Therapies

Docetaxel + Trametinib

Erlotinib + Trametinib

Trametinib

Pemetrexed + GSK1120212

Carboplatin + GSK1120212

nab-paclitaxel + GSK1120212

Gemcitabine + GSK1120212

Everolimus + GSK1120212

Age Groups: senior adult

No variant requirements are available.